Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial

This study (n=403) found use of vocimagene amiretrorepvec with flucytosine following tumour resection was not associated with a survival benefit in this patient population (median OS 11.10 months vs 12.22 months for standard of care; HR 1.06; 95% CI 0.83-1.35; P=0.62).

JAMA Oncology